Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
NMDC Steel Ltd, Piramal Pharma Ltd, PNC Infratech Ltd, Indus Towers Ltd are among the other stocks to see a surge in volumes on NSE today, 03 September 2025.
TBO Tek Ltd clocked volume of 41.36 lakh shares by 14:14 IST on NSE, a 33.89 times surge over two-week average daily volume of 1.22 lakh shares. The stock gained 13.56% to Rs.1,570.00. Volumes stood at 1.04 lakh shares in the last session.
NMDC Steel Ltd notched up volume of 533.84 lakh shares by 14:14 IST on NSE, a 11.6 fold spurt over two-week average daily volume of 46.02 lakh shares. The stock rose 9.99% to Rs.43.15. Volumes stood at 72.5 lakh shares in the last session.
Piramal Pharma Ltd clocked volume of 214.85 lakh shares by 14:14 IST on NSE, a 8.81 times surge over two-week average daily volume of 24.39 lakh shares. The stock gained 6.93% to Rs.199.65. Volumes stood at 20.27 lakh shares in the last session.
PNC Infratech Ltd recorded volume of 15.25 lakh shares by 14:14 IST on NSE, a 6.12 times surge over two-week average daily volume of 2.49 lakh shares. The stock gained 1.91% to Rs.309.70. Volumes stood at 2.24 lakh shares in the last session.
Indus Towers Ltd clocked volume of 446.3 lakh shares by 14:14 IST on NSE, a 5.66 times surge over two-week average daily volume of 78.91 lakh shares. The stock lost 1.75% to Rs.323.70. Volumes stood at 85.58 lakh shares in the last session.
Piramal Pharma Solutions and NewAmsterdam Pharma Company N.V. today announced the opening of a dedicated oral solid dosage (OSD) form suite at Piramal's facility in Sellersville, Pennsylvania, USA. As one of Piramal Pharma Solutions' focused drug product facilities, the Sellersville site provides comprehensive development and manufacturing services for various formulations, including several forms of OSDs. This addition will increase operational efficiency, helping NewAmsterdam Pharma to deliver its investigational drug therapy, if approved, to patients in need.
The suite represents a multi-million-dollar investment in equipment upgrades and enhancements to improve the site's capabilities. This includes a reconfiguration of existing space to create a dedicated OSD suite that will be used exclusively for fixed dose combination products. The new suite is designed for turnkey, multi-layer tablet production, equipped with advanced capabilities and technology to support granulation, compression, tableting, and coating.
This suite will facilitate the production of NewAmsterdam Pharma's investigational FDC, a non statin cholesterol medication to reduce LDL-C.
Although the suite is essential to the FDC's production, the partnership between Piramal Pharma Solutions and NewAmsterdam Pharma extends beyond the Sellersville site. Piramal's Ahmedabad PPDS, India site played a crucial role in the product's development, while its Pithampur, India site provides dual sourcing support.